About Amgen Inc.
https://www.amgen.comAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.
CEO
Robert A. Bradway
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1999-11-22 | Forward | 2:1 |
| 1999-03-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 1,029
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
BMO Capital
Outperform
RBC Capital
Outperform
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Wells Fargo
Equal Weight
Cantor Fitzgerald
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:53.88M
Value:$17.72B
BLACKROCK INC.
Shares:46.04M
Value:$15.15B
BLACKROCK, INC.
Shares:46.03M
Value:$15.14B
Summary
Showing Top 3 of 3,738
About Amgen Inc.
https://www.amgen.comAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $9.56B ▲ | $3.95B ▲ | $3.22B ▲ | 33.65% ▲ | $5.98 ▲ | $5.91B ▲ |
| Q2-2025 | $9.17B ▲ | $3.51B ▼ | $1.43B ▼ | 15.62% ▼ | $2.66 ▼ | $3.62B ▼ |
| Q1-2025 | $8.15B ▼ | $4B ▲ | $1.73B ▲ | 21.23% ▲ | $3.22 ▲ | $4.08B ▲ |
| Q4-2024 | $9.09B ▲ | $3.66B ▲ | $627M ▼ | 6.9% ▼ | $1.17 ▼ | $2.93B ▼ |
| Q3-2024 | $8.5B | $3.15B | $2.83B | 33.28% | $5.27 | $5.27B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $9.45B ▲ | $90.14B ▲ | $80.52B ▲ | $9.62B ▲ |
| Q2-2025 | $8.03B ▼ | $87.9B ▼ | $80.47B ▼ | $7.43B ▲ |
| Q1-2025 | $8.81B ▼ | $89.37B ▼ | $83.16B ▼ | $6.21B ▲ |
| Q4-2024 | $11.97B ▲ | $91.84B ▲ | $85.96B ▲ | $5.88B ▼ |
| Q3-2024 | $9.01B | $90.88B | $83.36B | $7.53B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.22B ▲ | $4.68B ▲ | $-414M ▼ | $-2.85B ▼ | $1.42B ▲ | $4.25B ▲ |
| Q2-2025 | $1.43B ▼ | $2.28B ▲ | $-389M ▲ | $-2.67B ▲ | $-782M ▲ | $1.91B ▲ |
| Q1-2025 | $1.73B ▲ | $1.39B ▼ | $-447M ▼ | $-4.11B ▼ | $-3.16B ▼ | $980M ▼ |
| Q4-2024 | $627M ▼ | $4.77B ▲ | $-402M ▼ | $-1.41B ▲ | $2.96B ▲ | $4.4B ▲ |
| Q3-2024 | $2.83B | $3.57B | $-210M | $-3.65B | $-290M | $3.31B |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Aranesp | $310.00M ▲ | $360.00M ▲ | $340.00M ▼ | $360.00M ▲ |
 BLINCYTO | $380.00M ▲ | $380.00M ▲ | $370.00M ▼ | $390.00M ▲ |
 ENBREL | $1.01Bn ▲ | $600.00M ▼ | $510.00M ▼ | $580.00M ▲ |
 EVENITY | $430.00M ▲ | $520.00M ▲ | $440.00M ▼ | $540.00M ▲ |
 KRYSTEXXA | $350.00M ▲ | $350.00M ▲ | $240.00M ▼ | $320.00M ▲ |
 Kyprolis | $370.00M ▲ | $380.00M ▲ | $320.00M ▼ | $360.00M ▲ |
 Nplate | $340.00M ▲ | $370.00M ▲ | $310.00M ▼ | $460.00M ▲ |
 Otezla | $620.00M ▲ | $620.00M ▲ | $440.00M ▼ | $580.00M ▲ |
 Other Products | $4.27Bn ▲ | $1.69Bn ▼ | $1.65Bn ▼ | $1.85Bn ▲ |
 Product and Service Other | $1.05Bn ▲ | $410.00M ▼ | $280.00M ▼ | $420.00M ▲ |
 Prolia | $1.17Bn ▲ | $1.12Bn ▼ | $1.10Bn ▼ | $1.14Bn ▲ |
 Repatha evolocumab | $610.00M ▲ | $700.00M ▲ | $660.00M ▼ | $790.00M ▲ |
 TEPEZZA | $460.00M ▲ | $510.00M ▲ | $380.00M ▼ | $560.00M ▲ |
 TEZSPIRE | $300.00M ▲ | $340.00M ▲ | $280.00M ▼ | $380.00M ▲ |
 Vectibix | $250.00M ▲ | $300.00M ▲ | $270.00M ▼ | $280.00M ▲ |
 XGEVA | $560.00M ▲ | $530.00M ▼ | $570.00M ▲ | $540.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $3.04Bn ▲ | $2.39Bn ▼ | $2.21Bn ▼ | $2.45Bn ▲ |
 UNITED STATES | $7.07Bn ▲ | $6.75Bn ▼ | $5.66Bn ▼ | $6.32Bn ▲ |
CEO
Robert A. Bradway
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1999-11-22 | Forward | 2:1 |
| 1999-03-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 1,029
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
BMO Capital
Outperform
RBC Capital
Outperform
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Wells Fargo
Equal Weight
Cantor Fitzgerald
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:53.88M
Value:$17.72B
BLACKROCK INC.
Shares:46.04M
Value:$15.15B
BLACKROCK, INC.
Shares:46.03M
Value:$15.14B
Summary
Showing Top 3 of 3,738